In antibody directed enzyme prodrug therapy (ADEPT) an antibody bound enzyme is targeted to tumor cells. This allows for selective activation of a nontoxic prodrug to a cytotoxic agent at the tumor site for cancer therapy. Site-selective prodrug activation results in reduced side effects in remote tissue. This article reviews ADEPT with emphasis on the chemical viewpoint and recent developments.
No takes yet. Share an insight, caveat, or question.
Manfred Jung (2001) studied this question.